Meclizine's Anticholinergic Properties Significantly Increase Fall Risk in Elderly Patients
Yes, meclizine's anticholinergic activity substantially increases the risk of falls in elderly patients and should be avoided or minimized in this population. The evidence consistently demonstrates that anticholinergic medications, including meclizine, are associated with injurious falls through multiple mechanisms including impaired cognition, visual disturbances, and balance deficits.
Evidence for Anticholinergic-Related Fall Risk
The relationship between anticholinergic burden and falls is well-established in geriatric medicine:
Anticholinergic medications are associated with injurious falls, episodes of confusion or delirium, emergency department visits, and hospitalizations through their broad muscarinic receptor blockade affecting vision, urination, constipation, and cognition 1.
The Drug Burden Index demonstrates that drugs with strong anticholinergic properties are associated with decline in cognition, functional status, and activities of daily living (ADL) scores in older patients 1.
Exposure to medications with highly anticholinergic properties should be minimized in older persons, with alternative medications used where anticholinergic drugs are indicated 2.
Specific Evidence on Meclizine and Falls
Recent high-quality research provides direct evidence linking meclizine to falls:
A 2025 cohort study of 805,454 adults with dizziness found that meclizine prescription was associated with subsequent falls in those aged 18-64 years (hazard ratio 2.94; 95% CI, 2.81-3.08) and those aged ≥65 years (hazard ratio 2.54; 95% CI, 2.42-2.66) 3.
Among patients prescribed meclizine, 9% overall experienced an injurious fall (10% in ages 18-64 and 9% in ages ≥65) 3.
The study concluded that meclizine use is incongruent with guideline-concordant care for common vestibular diagnoses 3.
Mechanisms of Anticholinergic-Related Falls
The pathophysiology involves multiple systems:
Anticholinergic side effects include muscle weakness, blurred vision, and mental confusion, all of which directly increase falls risk 4.
The association between anticholinergic burden and falls is mediated through gait and balance impairment rather than muscular weakness alone 5.
Long-term effects may extend beyond the period of drug use due to cognitive and physical deconditioning following initial anticholinergic exposure 4.
Dose-Response Relationship
The fall risk increases with anticholinergic burden:
Studies show most significant associations with moderate to high levels of anticholinergic burden 6.
Hazard ratios for fall hospitalization increase progressively: ACB score of 1 (HR 1.20), ACB 2-3 (HR 1.42), and ACB ≥4 (HR 1.39) compared to no anticholinergic exposure 7.
Any use of medications with anticholinergic properties showed an unadjusted incidence rate ratio of 1.79 (95% CI 1.66-1.93) for fall hospitalization over 19 years 7.
Clinical Context: Vestibular Suppressants and Falls
Guidelines specifically address vestibular suppressants like meclizine:
Vestibular suppressant medications are not routinely recommended for treatment of BPPV, except for short-term management of severe autonomic symptoms 8.
Psychotropic medications such as benzodiazepines are a significant independent risk factor for falls, and vestibular suppressants carry similar risks 8.
Patients with BPPV should be counseled regarding the risk of falls, particularly in elderly and frail populations who are more susceptible to serious injury 8.
FDA Labeling Considerations
The FDA label for meclizine acknowledges relevant concerns:
Meclizine should be used with caution due to its potential anticholinergic action 9.
The label notes that drowsiness may occur, and patients should be cautioned against driving or operating dangerous machinery 9.
Dose selection for elderly patients should be cautious, starting at the low end of the dosing range 9.
Clinical Recommendations
Deprescribing Strategy
Strongly anticholinergic medications including older antihistamines should be deprescribed in older patients 1.
Alternative medications without anticholinergic properties should be substituted for specific indications 2.
The liabilities associated with anticholinergic medications—injurious falls, confusion, delirium, ED visits, and hospitalizations—all raise the cost of care 1.
Risk Assessment
Polypharmacy (four or more prescription medications) is an established fall risk factor with OR 1.7 for psychotropic medications 10.
Older adults with diabetes are at increased risk for injurious falls and should be screened for fall risk 11.
The risk of falling increases dramatically as the number of risk factors increases 10.
Common Pitfalls to Avoid
Do not prescribe meclizine routinely for dizziness or vertigo without considering the fall risk, especially in elderly patients 3.
Avoid combining meclizine with other CNS depressants including alcohol, which increases CNS depression 9.
Do not assume younger patients are immune—the 2025 study showed increased fall risk even in patients aged 18-64 years 3.
Recognize that cumulative anticholinergic burden matters—patients taking multiple medications with mild anticholinergic properties face increased risk 4.